GlassScriptPhysician profile
Tamika K Cross
NPI 1144562364
$2,257.62
in general payments reported to CMS, 2019-2025
19 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $218 · 2021: $194 · 2022: $344 · 2023: $182 · 2024: $539 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.28 | 2019-2022 | |
| Hologic Sales and Service, LLC | $485.07 | 2019-2024 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Innovation Technologies INC | $214.70 | 2024-2025 | Irrisept |
| Galderma Laboratories, L.P. | $127.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $114.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $112.51 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2020 | |
| Mayne Pharma Commercial LLC | $97.40 | 2022-2023 | |
| Smith+Nephew, INC. | $80.89 | 2019 | |
| Cytyc Surgical Products, LLC | $67.07 | 2025 | Acessa Provu System, Novasure, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Evofem Biosciences, INC. | $48.93 | 2021-2022 | |
| Baxter Healthcare | $45.63 | 2025 | Perclot |
| Sumitomo Pharma America, INC. | $24.20 | 2024 | Myfembree |
| Gynesonics, INC. | $23.69 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Pfizer INC. | $23.18 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.00 | 2025 | Veozah |
| Organon LLC | $17.32 | 2025 | Nexplanon |
| Medtronic, INC. | $14.67 | 2021 | |
| Minerva Surgical, INC | $13.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamika Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.